Muthiah Vaduganathan, MD, MPH, is a cardiologist specializing in cardiorenal metabolism at Brigham and Women's Hospital in Boston, MA. Vaduganathan is a member of Practical Cardiology's advisory board and co-host of Don't Miss a Beat, a podcast presented by Inside Cardiology.

Understanding the Link Between Early CKD Diagnosis and Cardiovascular Outcomes

This episode, titled, ‘Understanding the Link Between Early CKD Diagnosis and Cardiovascular Outcomes,’ features panelists discussing the following critical question:

How can early identification of CKD in patients with T2D influence cardiovascular disease outcomes?

Led by the moderator, the experts focus on strengthening the link between early CKD diagnosis and cardiovascular risk by reframing urine albumin–creatinine ratio (uACR) as a systemic endothelial marker rather than a kidney-specific test. They discuss evidence showing that uACR is a powerful, inexpensive predictor of cardiovascular events—often outperforming traditional markers like lipids or hs-CRP—because it reflects widespread vascular and endothelial injury. The conversation highlights decades of epidemiologic data demonstrating that CKD and albuminuria act as multiplicative risk factors for coronary disease, heart failure, and cardiovascular mortality, underscoring the urgency of acting on this information now rather than allowing continued delays in practice adoption. Panelists emphasize shared responsibility across specialties to incorporate uACR into risk assessment, engage patients in understanding their cardiovascular implications, and deploy available therapies early to meaningfully reduce downstream risk.

In the next episode, ‘Emphasizing Multidisciplinary Collaboration for Early CKD Diagnosis,’ panelists will continue their discussion on chronic kidney disease and highlight the shift toward a shared "community of responsibility" where all specialties must move past clinical complacency to actively own CKD screening and management. The experts explore overcoming practical barriers—such as workflow challenges and the transition to routine urine-based testing—to ensure high-risk patients no longer fall through the cracks of a siloed healthcare system.

Videos

Why CKD screening lags despite aligned KDIGO, ADA and hypertension guidance—use eGFR plus UACR staging and EHR prompts to act earlier.

Video Series

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Quality of Life Impact of Delayed CKD Diagnosis

In ‘Quality of Life Impact of Delayed CKD Diagnosis,’ our experts delve into the following critical question:

How does delayed diagnosis of CKD affect patients’ quality of life and clinical outcomes, and how do these consequences reinforce the need for earlier identification in primary care?

Led by the moderator, the experts explore how to elevate the priority of CKD testing by reframing it around patient-centered outcomes, particularly quality of life and the heavy physical, emotional, and financial burdens associated with progression to end-stage kidney disease and dialysis. They emphasize that delayed CKD diagnosis amplifies cardiovascular risk, worsens comorbid conditions such as diabetes and heart failure, and increasingly constrains therapeutic options across many diseases. The discussion highlights that early-stage CKD is now a modifiable condition, with effective lifestyle and pharmacologic tools—such as RAS inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRAs—that can meaningfully reduce kidney and cardiovascular risk when applied early. Panelists also challenge the false reassurance that dialysis is an adequate safety net, underscoring instead the high mortality, profound patient burden, and missed opportunities that result from diagnostic and therapeutic inertia.

Our next episode, ‘Understanding the Link Between Early CKD Diagnosis and Cardiovascular Outcomes,’ further explores chronic kidney disease, highlighting the reframing of uACR as a systemic marker of endothelial health that serves as a powerful, multiplicative predictor of cardiovascular events beyond traditional lipid or CRP testing. The panel emphasizes the urgency of translating decades of epidemiological evidence into immediate clinical practice to trigger aggressive, early intervention for high-risk patients.

CKD guidelines agree: use eGFR plus UACR for KDIGO staging, but screening lags—see how teams and EHRs close the gap.

Quality of Life Impact of Delayed CKD 

Timothy E. Dribin, from the division of emergency medicine, at Cincinnati Children’s Hospital Medical Center.

International Consensus on Epinephrine Use, With Timothy E. Dribin, MD

Uncertainty around when patients should administer epinephrine for 

 in community settings prompted an international expert panel to develop consensus-based recommendations.

 The resulting report aims to reduce persistent variation in anaphylaxis action plans.

 spoke with first author Timothy E. Dribin, MD, from the division of emergency medicine, at Cincinnati Children’s Hospital Medical Center, on what clinical gap prompted this international consensus on epinephrine and EMS activation, and how this report addresses both underuse and overuse of epinephrine in community settings.

“The number one question that I get when patients leave our emergency departments, when we prescribe them an autoinjector, is: when should I administer epinephrine? What symptoms should I administer epinephrine for? It's a very complicated answer because there's no consensus on what symptoms warrant epinephrine and what symptoms do not warrant epinephrine,” Dribin said.

He continued by saying that different organizations have their own action plans. Recommendations differ from country to country.

“To address that gap, we said, ‘look, it'd be really helpful if we could have some international recommendations based on the views of an expert panel to try to resolve that variation and come up with consensus around…when…patients [should] administer epinephrine,’” Dribin said. “It is important to note, though, that in clinical practice, we always say if in doubt, patients and caregivers should just err on the side of giving epinephrine, given that it's a very, very safe medicine.”

Although early intramuscular epinephrine remains the first-line treatment for anaphylaxis, real-world studies suggest it is underused. Dribin noted that only approximately 21% of children and 7% of adults with anaphylaxis receive epinephrine before arriving at the emergency department. Delayed or absent epinephrine has been associated with worse outcomes, including increased hospitalization risk.

To address this variability, investigators convened a 34-member international panel from January 2024 through May 2025 and used a modified Delphi process to develop structured clinical scenarios reflecting differing severities and organ system involvement.

The panel categorized reactions across 4 organ systems: cutaneous or mucosal, respiratory, cardiovascular, and gastrointestinal. They generated 24 clinical scenarios representing isolated and combined system involvement, along with 9 candidate modifiers that could lower the threshold for epinephrine administration, such as comorbid asthma, and 12 potential EMS activation recommendations.

In phase 1 of the Delphi process, 21 of 24 scenarios reached consensus recommending epinephrine administration. Two scenarios reached consensus against epinephrine use, and one did not achieve consensus.

Agreement was strongest when reactions involved ≥ 2 organ systems. Isolated but severe respiratory symptoms, such as wheezing or dyspnea, and cardiovascular symptoms, including dizziness or hypotension, also generated high agreement for immediate epinephrine administration.

In contrast, isolated mild cutaneous symptoms, such as limited urticaria, or mild gastrointestinal symptoms, did not warrant epinephrine according to panel consensus. The single scenario that failed to reach consensus involved moderate mucocutaneous symptoms without other organ involvement. Dribin emphasized that this reflects real-world variability in clinician and caregiver risk tolerance.

The panel achieved consensus on 5 modifiers and 10 EMS activation recommendations. In phase 2, investigators embedded consensus modifiers into scenarios that initially did not recommend epinephrine or lacked consensus. Only 2 of 15 reassessed scenarios subsequently reached consensus for epinephrine administration, suggesting that modifiers did not broadly shift decision thresholds.

Dribin acknowledged that although underuse remains the larger public health concern, overuse carries implications. Administration of epinephrine typically prompts EMS activation or emergency department evaluation, which can result in healthcare expenditures, missed school or work, and patient anxiety.

For clinicians, Dribin advised contextual interpretation of the consensus statements, particularly in scenarios where agreement was not reached. He cautioned against viewing the recommendations as prescriptive mandates, noting that shared decision-making and individualized counseling remain central.

“Ultimately, what we are doing right now is we're trying to build a smartphone application that can incorporate these algorithms, so that in real time, patients and caregivers can receive prescriptive advice about whether to administer epinephrine,” Dribin said. “…it will also spur them to observe their symptoms and either re-dose epinephrine, or for those reactions where they didn't initially administer epinephrine, if their reactions were to get worse, it would make sure that they're checking their symptoms and then administering that device.”

Dribin TE, Sampson HA, Anagnostou A, et al. Epinephrine and emergency medical services activation recommendations during acute allergic reactions in community settings: International consensus report. 

Golden DBK, Wang J, Waserman S, et al. Anaphylaxis: A 2023 practice parameter update. 

Expert panel identifies high agreement for multi-organ involvement, but uncertainty remains in moderate isolated skin or mucosal symptoms.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Dry powder and soft mist inhalers in the long-acting muscarinic antagonist–long-acting β-agonist (LAMA–LABA) class were associated with modestly lower exacerbation risk in people with 

 (COPD) compared with a metered-dose inhaler (MDI) in a large US claims-based study published in 

“The inhalers we studied are the first line treatment for many patients with COPD, so it’s reassuring to see evidence that lower-emission inhalers may also be associated with slightly better clinical outcomes,” William Feldman, a pulmonologist and health services researcher at UCLA Health and the study’s senior author, wrote.

 “These findings highlight the opportunity to reduce healthcare-related emissions while potentially improving patient care.”

COPD affects more than 16 million US adults and remains a leading cause of hospitalization and death.

 Prevention of moderate and severe exacerbations is central to management, and dual bronchodilator therapy with LAMA–LABA combinations is recommended for many symptomatic patients.

 MDIs commonly use hydrofluoroalkane propellants, which have high global warming potential, whereas dry powder inhalers (DPIs) and soft mist inhalers (SMIs) do not require propellants and have substantially lower associated emissions.

The new study’s findings add comparative effectiveness data to ongoing discussions about inhaler selection in COPD, including consideration of environmental impact.

Feldman and colleagues conducted a retrospective, matched cohort study using commercial and Medicare Advantage claims from 2016 through 2025, including adults aged 40 years or older initiating a LAMA–LABA inhaler.¹ Three pairwise matched cohorts were constructed:

9,479 matched pairs receiving umeclidinium–vilanterol (DPI) vs glycopyrrolate–formoterol (MDI) (mean age, 68.9 years; standard deviation [SD], 9.0; 10,319 women, 54.4%; 8,636 men, 45.6%)

9,598 matched pairs receiving tiotropium–olodaterol (SMI) vs MDI (mean age, 69.2 years; SD, 8.7; 10,513 women, 54.8%; 8,680 men, 45.2%)

36,740 matched pairs receiving DPI vs SMI (mean age, 71.5 years; SD, 8.4; 39,429 women, 53.7%; 34,044 men, 46.3%)

The primary outcome was time to first moderate or severe COPD exacerbation. Safety outcomes included first major adverse cardiovascular event, urinary tract infection, and pneumonia hospitalization.

Portela and colleagues found that compared with MDI, DPI was associated with a 14% lower hazard of a first moderate or severe exacerbation (hazard ratio [HR], 0.86; 95% CI, 0.81-0.91), corresponding to a number needed to treat (NNT) of 17.¹ SMI was associated with a 6% lower hazard compared with the MDI (HR, 0.94; 95% CI, 0.89-1.00).¹

In a direct comparison between the 2 lower-emission devices, DPI was associated with a 3% lower hazard than tiotropium–olodaterol (HR, 0.97; 95% CI, 0.94-0.99), with an NNT of 100.¹ Absolute differences were modest across comparisons.

 Retrospective matched cohort analysis (2016–2025 claims data)

 Adults ≥40 years initiating LAMA–LABA therapy

 First moderate or severe COPD exacerbation

DPI vs MDI: HR 0.86 (95% CI, 0.81-0.91); NNT 17

DPI vs SMI: HR 0.97 (95% CI, 0.94-0.99); NNT 100

 Similar risks of MACE, UTI, pneumonia hospitalization

 DPIs and SMIs avoid high–global warming potential propellants

Safety outcomes were similar across all 3 cohorts, with no meaningful differences in risks of major adverse cardiovascular events, urinary tract infections, or pneumonia hospitalization.¹

Although randomized trials have established the efficacy of dual bronchodilators, head-to-head comparisons across inhaler platforms are limited.⁵ The present study suggests that, in routine practice, certain lower-emission inhalers may be associated with slightly fewer exacerbations without added safety risk.

However, as an observational analysis, the findings are subject to residual confounding. Claims data lack spirometry, symptom burden, and inhaler technique measures, and adherence patterns may differ by device. The modest hazard differences—particularly the 3% relative reduction between DPI and SMI—should be interpreted cautiously.

“This combination makes a strong case for using DPIs when possible,” Feldman said.

 “Although some patients may require MDIs, DPIs and SMIs are a safe and effective option for most patients with COPD.”

From an environmental standpoint, inhaler propellants contribute to healthcare-associated greenhouse gas emissions. When clinical outcomes are comparable, device selection may reasonably incorporate environmental considerations alongside patient ability, inspiratory flow capacity, and cost.

Altogether, the study supports consideration of DPIs or SMIs when appropriate from a clinical and patient-centered standpoint. While the magnitude of benefit was small, the absence of increased safety risk and the lower carbon footprint of these devices may inform shared decision-making in COPD management.

Feldman WB, et al. Comparative effectiveness and environmental impact of LAMA–LABA inhalers in chronic obstructive pulmonary disease. 

. Published online 2026. doi:10.1001/jamainternmed.2025.8087. 

https://doi.org/10.1001/jamainternmed.2025.8087

Dry powder inhalers show promise for COPD and the environment. News release. UCLA Health. February 23, 2026. 

https://www.uclahealth.org/news/release/dry-powder-inhalers-show-promise-copd-and-environment

Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease (COPD). Updated 2024. 

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Prevention, Diagnosis and Management of COPD, 2024 Report. 

Articles

A large US claims-based matched cohort analysis comparing LAMA–LABA delivery platforms in COPD found modestly lower exacerbation risk with lower-emission devices. Dry powder inhalers (umeclidinium–vilanterol) reduced time to first moderate/severe exacerbation versus metered-dose inhalers (glycopyrrolate–formoterol) (HR 0.86; NNT 17), while soft mist inhalers (tiotropium–olodaterol) showed a smaller benefit (HR 0.94). Dry powder also slightly outperformed soft mist (HR 0.97; NNT 100). Safety outcomes were similar across platforms, supporting environmentally informed, patient-centered device selection.

Claims study suggests dry powder and soft mist COPD inhalers cut exacerbations versus MDIs, offering greener care without added safety risks.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Lower-Carbon LAMA–LABA Inhalers Linked to Modest Reductions in COPD Exacerbation Risk

Joshua Rothman, MD, MS, is a clinical assistant professor in the department of pediatrics and Medical Director of Informatics Academic Pediatrics at the University of California San Diego.

Could Falling Hepatitis B Vaccine Rates Reverse Decades of Progress?

For decades, universal newborn vaccination against hepatitis B has been a cornerstone of pediatric preventive care in the United States, widely regarded not only as protection against viral infection, but as a powerful tool in preventing chronic liver disease and liver cancer later in life.

 suggest that uptake of the birth dose may be slipping at a pivotal moment. Against a backdrop of evolving vaccine policy and shifting public discourse around immunization, these findings raise urgent questions about whether progress toward hepatitis B elimination could be at risk.

In discussing the findings from his research, Joshua Rothman, MD, MS, a clinical assistant professor in the department of pediatrics and Medical Director of Informatics Academic Pediatrics at the University of California San Diego, emphasized the critical importance of hepatitis B vaccination in infancy.

“Infants who are infected with hepatitis B in the first year of their life have up to a 90% risk of developing chronic hepatitis B, and that's associated with liver disease and cancer,” he explained. “Iif you think about it, the hepatitis B vaccine, especially in the early stages of life, is really like an anti-cancer vaccine.”

He goes on to explain how the rationale for administering the hepatitis B vaccine at birth is rooted in prevention of unexpected exposures. While maternal screening during pregnancy is standard, Rothman noted that false-negative maternal tests can occur. In addition, infants may be exposed through household members, caregivers, or delayed follow-up care. As such, the birth dose functions as a critical safety net, offering protection during a vulnerable period when the risk of progression to chronic infection is highest.

The study found that rates of the newborn hepatitis B vaccine declined by more than 10% over the past 2 years in the United States. Of note, this decline occurred before updated recommendations from the Advisory Committee on Immunization Practices (ACIP) in December 2025 and subsequent updated guidance from the Centers for Disease Control and Prevention (CDC) in January 2026. Rothman underscored that because the data predate these policy changes, vaccination rates may decline even further following the new guidance.

When considering possible drivers of the decrease, Rothman pointed to broader shifts in public discourse surrounding vaccines.

“I would say that coming out of the COVID-19 pandemic, there was a concern about messaging around the COVID vaccine, and then that conversation seemed to shift into childhood vaccinations in general,” he said.

While chronic hepatitis B rates in the United States have been declining for years, in large part due to vaccination efforts, Rothman cautioned that sustained declines in vaccination coverage could halt this progress or even reverse it. He says a reduction in early-life immunization may lead to an increase in pediatric infections, with long-term consequences that include chronic liver disease and liver cancer decades later.

Despite growing safety concerns among some parents, Rothman stressed that the hepatitis B vaccine has decades of evidence supporting its safety and efficacy. For pediatricians and healthcare providers, he said, the goal remains clear: eliminate hepatitis B, both nationally and globally. Until that goal is achieved, he emphasized the need for continued vigilance in counseling families about the importance of early, evidence-based protection.

Editors’ Note: Rothman reports no relevant disclosures.

Rothman JM, Kwan B, Longhurst CA, Jena AB. US Newborn Hepatitis B Virus Vaccination Rates. JAMA. Published online February 23, 2026. doi:10.1001/jama.2026.0866

Brooks A. CDC Changes Infant Hepatitis B Vaccine Recommendation. HCPLive. December 5, 2025. Accessed February 25, 2026. 

https://www.hcplive.com/view/cdc-changes-infant-hepatitis-b-vaccine-recommendation

New data show a >10% drop in newborn hepatitis B vaccination, raising concern for rising chronic infection and future liver cancer risk.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Declining Hepatitis B Birth Dose Rates and the Risk to Long-Term Liver Health, With Joshua Rothman, MD, MS

This February episode of The Medical Sisterhood highlights key points on juggling work as a clinician and work as a mother.

The Medical Sisterhood, with Mona Shahriari, MD

The Medical Sisterhood, hosted by Mona Shahriari, MD, is a podcast dedicated to empowering female physicians by providing a platform for shared experiences, mentorship, and support. 

Each episode delves into the unique challenges women in medicine face, including work-life balance, leadership roles, and overcoming gender biases. Shahriari aims to inspire women to lead fulfilling professional and personal lives on their own terms through candid discussions and expert interviews. 

e as we foster a community where women can uplift and support each other in achieving their goals!

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

The Medical Sisterhood: Physician Mom Burnout & Mental Health Strategies, With Jennifer Hsiao, MD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

The FDA has approved proprietary desmopressin oral solution formulation ET-600 for the treatment of central diabetes insipidus in children.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

FDA News

FDA Approves ET-600 Desmopressin Acetate (Desmoda) for Central Diabetes Insipidus

Mary K Roberts, PhD is a Post Doctoral Researcher at the Leverhulme Centre for Demographic Science at the University of Oxford.

Willingness to pursue living kidney donation is shaped by relationships, health, and a multidisciplinary approach, not just finances.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Living Donor Donation Works When Relationships Matter With Mary Roberts, PhD

Mark Creager, MD, is the director emeritus of the Heart and Vascular Center at Dartmouth University.

Creager discusses the accomplishments of the ACC and AHA’s joint PE clinical practice guideline while continuing to look to the future of the disease.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Strategic Alliance Partnership

New Pulmonary Embolism Guidelines Highlight Progress, Encourage Research, With Mark Creager, MD

Andres Hurtado-Lorenzo, PhD, is VP of IBD Ventures and Translational Research at the Crohn’s & Colitis Foundation.

Hurtado-Lorenzo discusses trial data showing time-restricted feeding in Crohn’s disease results in weight loss, symptom improvement, and microbiome changes.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

New Evidence on Meal Timing and Crohn’s Disease Outcomes, With Andres Hurtado-Lorenzo, PhD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Vanda Pharmaceuticals announced the FDA's acceptance of imsidolimab's Biologics License Application for the treatment of GPP.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

FDA Accepts BLA for Imsidolimab as Generalized Pustular Psoriasis Treatment

Matthew Jolley, MD, is the Topolewski Endowed Chair in Pediatric Cardiology at Children’s Hospital of Philadelphia.

Jolley discusses the team’s combination of volume rendering and cardiac MRI-based valve evaluation to provide 4D models of the heart and blood flow.

New Cardiac Imaging Method Directly Visualizes Pediatric Heart Defects, With Matthew Jolley, MD

Adrian Brown, PhD, NIHR Advanced Fellow and Associate Professor in Nutrition and Dietetics at University College London and programme co-lead of the MSc Dietetics (Pre-registration) course

Systematic review identifies patient and clinician barriers to obesity management before kidney transplantation, with Adrian Brown, PhD.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Barriers to Obesity Management in Kidney Failure Before Transplantation

Mauro Cancian, MD, PhD, head of the allergy division at the University of Padua.

Updated HAE guidelines support early self-treatment; Cancian discuss transitioning patients from injectable on-demand therapy to oral sebetralstat after KONFIDENT data.

Transitioning to Oral On-Demand HAE Therapy, With Mauro Cancian, MD, PhD

Rare kidney diseases are hard to detect early, but precision therapies and updated guidelines offer new ways to improve patient outcomes.


RDR Alert®

The Rare Disease Report page is a resource for medical news and expert insights on rare diseases. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for sickle cell disease, multiple myeloma, and more.

Latest News

Understanding the Link Between Early CKD Diagnosis and Cardiovascular Outcomes

Quality of Life Impact of Delayed CKD

International Consensus on Epinephrine Use, With Timothy E. Dribin, MD

Lower-Carbon LAMA–LABA Inhalers Linked to Modest Reductions in COPD Exacerbation Risk

Declining Hepatitis B Birth Dose Rates and the Risk to Long-Term Liver Health, With Joshua Rothman, MD, MS